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1. Introduction 
Nevoid basal cell carcinoma syndrome (NBCCS) is characterized by the presence of multiple 
basal cell carcinomas associated with palmoplantar pits (Gorlin 1960). The patients are 
normal at birth and the syndrome manifests as palmoplantar pits in their early childhood. In 
their teens, odontogenic keratocysts (jaw cysts) develops and they are the first complain to 
visit hospitals (Evans 1993). Basal cell carcinomas (BCCs) present in their 40’s, which is 
much earlier than sporadic BCCs. The other characteristic signs are bifid rib, calcification of 
the falx (Kimonis 1997). 
NBCCS is associated with a higher risk of medulloblastoma, and ovarian malignancies 
(figures 1, 2, 3). 
 
Figure 1. Multile BCCs on the face. 
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Figure 2. Palmar pits and its pathology. 
2. Inheritance 
Inheritance was autosomal dominant (Gorlin 1993). About 40% of cases represent a de novo 
mutation. It occurs in all races, and occurs in both sexes equally. The prevalence is reported 
to be 1 case per 56,000-164,000 population. 
No genotype/phenotype relations have been reported. 
3. Cutaneous presentation of NBCCS 
Palmoplantar pits are the earliest clinical signs in their childhood. The keratinocytes under 
the pits are BCC-like, and its keratinization is abnormal, therefore the reduced stratified 
corneum looks like a pit. 
 
Nevoid Basal Cell Carcinoma Syndrome (NBCCS) 139 
Multiple basal cell carcinomas usually develops over their 40’s. Usually sporadic BCC 
develops on the sun-exposed area in elderly people, especially on the face.  
However, in NBCCS, BCC can develop on any areas of the body, which are not generally 
exposed to sunlight, such as the palms and soles of the feet and in younger people. 
 
Figure 3. Multiple odontogenic keratocysts (jaw cysts) in the jaw. 
4. Molecular genetics of NBCCS and its molecular mechanism 
The responsible genes for NBCCS are the PTCH1 gene on chromosome 9q22, the PTCH2 
gene on 1q32 and the SUFU gene on 10q24-q25 (Johnson 1996, Hahn 1996, Smyth 1999, 
Pastorino 2009). These genes mutations result in abnormalities in sonic hedgehog (SHH) 
signaling pathway components, which lead to the development of basal cell carcinomas. The 
sequence of PTCH2 identities with 54 % of that of PTCH1. All three mammalian hedgehogs 
bind both receptors with similar affinity, so PTCH1 and PTCH2 cannot discriminate 
between the ligands.  
No founder effects have been reported and almost all mutations are speculated to be de novo. 
No genotype/phenotype relations have been reported. Each person who has this syndrome 
is affected to a different degree, some having many more characteristics of the condition 
than others (Tanioka 2005). 
Both PTCH1 and PTCH2 are coding a twelve transmembrane receptor whose lignad is sonic 
hedgehog (SHH)(Ingham 2011). SHH is a ~45kDa precursor and undergoes autocatalytic 
processing to produce an ~20kDa N-terminal signaling domain and a ~25kDa C-terminal 
domain with no known signaling role. SHH can signal in an autocrine fashion, affecting the 
cells in which it is produced.  
In the absence of SHH, PTCH1 inhibits Smoothened (SMO), which is a downstream 
membrane protein in the SHH pathway (Taipale 2002). SMO is regulated by a small 
molecule, the cellular localization of which is controlled by PTCH (Strutt 2001).  
The molecular mechanism is not fully understood, however, it should be associated with 
choresterol (Davies 2000). PTCH1 has a sterol sensing domain (SSD), which has been shown 
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to be essential for suppression of Smo activity. In addition, PTCH1 has homology to 
Niemann-Pick disease, type C1 (NPC1) that is known to transport lipophilic molecules 
across a membrane. It is believed that PTCH regulates SMO by removing oxysterols from 
SMO. PTCH acts like a sterol pump and removes oxysterols that have been created by 7-
dehydrocholesterol reductase. Upon binding of a SHH protein or a mutation in the SSD of 
PTCH the pump is turned off allowing oxysterols to accumulate around SMO.  
The binding of SHH relieves SMO inhibition, leading to activation of the GLI transcription 
factors: the activators Gli1 and Gli2 and the repressor Gli3 (Shimokawa 2006). The sequence 
of molecular events that connect SMO to GLIs is poorly understood. However, in NBSSC, it 
is believed that activated Gli leads to the upregulated cell cycle of BCC cells (Epstein 1998). 
Recently, some drugs that blocks the SHH pathways have been developed and many clinical 
trials are undergoing. 
5. Management of NBCCS 
Management is careful examination and monitoring for malignant degenerations. Surgical 
interventions of jaw cysts can correct or minimize deformities. Surgical removal of basal cell 
carcinomas and medulloblastomas are recommended. Recently, a drug, vismodegib, which 
target the SMO are proved to be effective to control unresectable BCC and newly 
development of BCCs in NBCCS patients (Sekulic 2012, Tang 2012). Vismodegib is a new 
orally administered hedgehog-pathway inhibitor that produces objective responses in 
locally advanced and metastatic basal cellcarcinomas. Vismodegib reduces the basal-cell 
carcinoma tumor burden and blocks growth of new basal-cell carcinomas in patients with 
the basal-cell nevus syndrome. The adverse events associated with treatment led to 
discontinuation in over half of treated patients. Those included loss of taste, muscle cramps, 
hair loss, and weight loss. 
Author details 
Miki Tanioka 
Department of Dermatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan 
6. References 
Aleksandar Sekulic, M.D., Ph.D., Michael R. Migden, M.D., Anthony E. Oro, M.D., Ph.D., 
Luc Dirix, M.D., Ph.D., Karl D. Lewis, M.D., John D. Hainsworth, M.D., James A. 
Solomon, M.D., Ph.D., Simon Yoo, M.D., Sarah T. Arron, M.D., Ph.D., Philip A. 
Friedlander, M.D., Ph.D., Ellen Marmur, M.D., Charles M. Rudin, M.D., Ph.D., Anne 
Lynn S. Chang, M.D., Jennifer A. Low, M.D., Ph.D., Howard M. Mackey, Ph.D., Robert 
L. Yauch, Ph.D., Richard A. Graham, Ph.D., Josina C. Reddy, M.D., Ph.D., and Axel 
Hauschild, M.D. Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma 
N Engl J Med 2012;366:2171-9. 
 
Nevoid Basal Cell Carcinoma Syndrome (NBCCS) 141 
Davies, J. P.; Chen, FW; Ioannou, YA (2000). "Transmembrane Molecular Pump Activity of 
Niemann-Pick C1 Protein". Science 290 (5500): 2295–8. 
Epstein, Ervin H.; De Sauvage, Frederic J.; Xie, Jingwu; Murone, Maximilien; Luoh, Shiuh-
Ming; Ryan, Anne; Gu, Qimin; Zhang, Chaohui et al. (1998). "Activating Smoothened 
mutations in sporadic basal-cell carcinoma". Nature 391 (6662): 90–2. 
Evans, D. G. R., Ladusans, E. J., Rimmer, S., Burnell, L. D., Thakker, N., Farndon, P. A. 
Complications of the naevoid basal cell carcinoma syndrome: results of a population 
based study. J. Med. Genet. 30: 460-464, 1993. 
Gorlin, R. J. From oral pathology to craniofacial genetics. Am. J. Med. Genet. 46: 317-334, 
1993. 
Gorlin, R. J., Goltz, R. W. Multiple nevoid basal-cell epithelioma, jaw cysts and bifid rib: a 
syndrome. New Eng. J. Med. 262: 908-912, 1960. 
Hahn, H., Wicking, C., Zaphiropoulos, P. G., Gailani, M. R., Shanley, S., Chidambaram, A., 
Vorechovsky, I., Holmberg, E., Unden, A. B., Gillies, S., Negus, K., Smyth, I., Pressman, 
C., Leffell, D. J., Gerrard, B., Goldstein, A. M., Dean, M., Toftgard, R., Chenevix-Trench, 
G., Wainwright, B., Bale, A. E. Mutations of the human homolog of Drosophila patched 
in the nevoid basal cell carcinoma syndrome. Cell 85: 841-851, 1996. 
Ingham, Philip W.; Nakano, Yoshiro; Seger, Claudia (2011). "Mechanisms and functions of 
Hedgehog signalling across the metazoa". Nature Reviews Genetics 12 (6): 393–406. 
Jean Y. Tang, M.D., Ph.D., Julian M. Mackay-Wiggan, M.D., Michelle Aszterbaum, M.D., 
Robert L. Yauch, Ph.D., Joselyn Lindgren, M.S., Kris Chang, B.A., Carol Coppola, R.N., 
Anita M. Chanana, B.A., Jackleen Marji, M.D., Ph.D., David R. Bickers, M.D., and Ervin 
H. Epstein, Jr., M.D. Inhibiting the Hedgehog Pathway in Patients with the Basal-Cell 
Nevus Syndrome N Engl J Med 2012;366:2180-8. 
Johnson, R. L., Rothman, A. L., Xie, J., Goodrich, L. V., Bare, J. W., Bonifas, J. M., Quinn, E. 
H., Myers, R. M., Cox, D. R., Epstein, E. H., Jr., Scott, M. P. Human homolog of patched, 
a candidate gene for the basal cell nevus syndrome. Science 272: 1668-1671, 1996. 
Kimonis, V. E., Goldstein, A. M., Pastakia, B., Yang, M. L., Kase, R., DiGiovanna, J. J., Bale, 
A. E., Bale, S. J. Clinical manifestations in 105 persons with nevoid basal cell carcinoma 
syndrome. Am. J. Med. Genet. 69: 299-308, 1997. 
Pastorino, L., Ghiorzo, P., Nasti, S., Battistuzzi, L., Cusano, R., Marzocchi, C., Garre, M. L., 
Clementi, M., Bianchi Scarra, G. Identification of a SUFU germline mutation in a family 
with Gorlin syndrome. Am. J. Med. Genet. 149A: 1539-1543, 2009. 
Shimokawa, Takashi; Rahnama, Fahimeh; Lauth, Matthias; Finta, Csaba; Kogerman, Priit; 
Teglund, Stephan; Toftgård, Rune; Zaphiropoulos, Peter G. (2006). "Inhibition of GLI1 
gene activation by Patched1" (//www.ncbi.nlm.nih.gov/pmc/articles/PMC1385998/) . 
Biochemical Journal 394 (Pt 1): 19–26. 
Smyth, I., Narang, M. A., Evans, T., Heimann, C., Nakamura, Y., Chenevix-Trench, G., 
Pietsch, T., Wicking, C., Wainwright, B. J. Isolation and characterization of human 
Patched 2 (PTCH2), a putative tumour suppressor gene in basal cell carcinoma and 
medulloblastoma on chromosome 1p32. Hum. Molec. Genet. 8: 291-297, 1999. 
 Current Genetics in Dermatology 142 
Strutt, H.; Thomas, C.; Nakano, Y.; Stark, D.; Neave, B.; Taylor, A.M.; Ingham, P.W. (2001). 
"Mutations in the sterol-sensing domain of Patched suggest a role for vesicular 
trafficking in Smoothened regulation". Current Biology 11 (8): 608–13. 
Taipale, J.; Cooper, M. K.; Maiti, T.; Beachy, P. A. (2002). "Patched acts catalytically to 
suppress the activity of Smoothened". Nature 418 (6900): 892–7. 
Tanioka M, Takahashi K, Kawabata T, Kosugi S, Murakami KI, Miyachi Y, Nishigori C and 
Iizuka T Germline mutations of the PTCH gene in Japanese patients with nevoid basal 
cell carcinoma syndrome. Arch Dermatol Res 296(7): 303-308, 2005. 
